Abstract | BACKGROUND: OBJECTIVES: To evaluate the efficacy of tamoxifen in improving the FH prediction (FHP) in patients with MAS. METHOD: We retrospectively analyzed 8 female patients with MAS who presented with café-au-lait spots and gonadotropin-independent PP. The patients were followed for a mean period of 8.3 years (range: 3-16). RESULTS: All patients were treated with tamoxifen (10-20 mg/day) for 3-8 years (mean ± SD: 5.75 ± 2.05), which resulted in the cessation of vaginal bleeding and the stabilization of bone age maturation. There was a significant difference between the FHP at the beginning of treatment and at the end of treatment (145.1 ± 8.6 cm; Z score -2.84 ± 1.44 cm) and at the last evaluation (157.0 ± 9.2 cm; Z score -0.85 ± 0.54 cm; p < 0.001). CONCLUSION: Our results support a role for tamoxifen in improving the FHP in patients with MAS.
|
Authors | Caroline de G Buff Passone, Hilton Kuperman, Hamilton Cabral de Menezes-Filho, Lygia Spassapan Oliveira Esteves, Rachel Lana Obata Giroto, Durval Damiani |
Journal | Hormone research in paediatrics
(Horm Res Paediatr)
Vol. 84
Issue 3
Pg. 184-9
( 2015)
ISSN: 1663-2826 [Electronic] Switzerland |
PMID | 26227563
(Publication Type: Journal Article)
|
Copyright | © 2015 S. Karger AG, Basel. |
Chemical References |
- Estrogen Antagonists
- Gonadotropins
- Tamoxifen
- Estradiol
|
Topics |
- Adolescent
- Body Height
(drug effects)
- Bone Development
(drug effects)
- Cafe-au-Lait Spots
(complications)
- Child
- Child, Preschool
- Estradiol
(blood)
- Estrogen Antagonists
(adverse effects, therapeutic use)
- Female
- Fibrous Dysplasia, Polyostotic
(drug therapy, pathology)
- Follow-Up Studies
- Gonadotropins
(blood)
- Humans
- Ovary
(pathology)
- Puberty, Precocious
(prevention & control)
- Retrospective Studies
- Tamoxifen
(adverse effects, therapeutic use)
- Treatment Outcome
|